We are extremely pleased with the progress in building our business, said S. Wayne Kay, chief executive officer, Response. Our strong partnerships are beginning to pay dividends and we believe the trend of strong year-over-year revenue growth will continue as we move toward eventual profitability. Our state-of-the-art manufacturing facility has afforded us greater production capacity, which is important, as Roche Diagnostics successfully launched our cardiovascular products in the U.S. and, coupled with 3M selling our influenza product, should allow us to take advantage of our larger manufacturing scale.